A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...

A test measuring proteins in spinal fluid may help support the diagnosis of MS, especially in patients whose disease is harder to diagnose.

The U.S. FDA granted Roche Holding AG breakthrough device designation for its Elecsys Neurofilament Light Chain test for multiple sclerosis. The Elecsys NfL test can aid in the detection of disease ...

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the ...

A new test that can detect iron levels in different parts of the brain may revolutionize how multiple sclerosis is diagnosed and treated. Share on Pinterest A new test may be able to predict the ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...

Researchers from the MPI of Biochemistry and the Technical University of Munich have discovered new diagnostic markers for multiple sclerosis (MS), a disease that affects 3 million people worldwide.

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...

MULTIPLE sclerosis was recognized as a clinical entity early in the nineteenth century by Charcot. Since then its pathology and clinical symptomatology have been defined, but the etiology of this ...

Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.